Skip to content

Hypnotherapy for adolescents and adults with inflammatory bowel disease and symptoms compatible with irritable bowel syndrome

Hypnotherapy for adolescents and adults with inflammatory bowel disease and symptoms compatible with irritable bowel syndrome - HIPI: Hypnotherapy for IBD Patients with IBS like symptoms

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON34040
Enrollment
80
Registered
2012-08-24
Start date
2012-03-01
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohns disease inflammatory bowel disease Ulcerative Colitis

Interventions

Patients in the hypnotherapy group will receive 6 sessions of 50 minutes therapy over a 3-months period. The hypnotherapy-protocol used is based on the Manchester protocol of gut-directed hypnothera

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
12 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with inflammatory bowel disease and IBS-like symptoms, age >11 years will be recruited. Patients have to be in remission of their inflammatory bowel disease as defined as no signs of inflammatory bowel disease, low inflammatory markers in laboratory tests and no disease activity on imaging studies of the intestine. IBS-like symptoms are defined as abdominal pain for at least two months, fulfilling the pediatric and adult Rome-III criteria for IBS

Exclusion criteria

Exclusion criteria: Exclusion criteria are a concomitant organic gastrointestinal disease, treatment by another health care professional for abdominal symptoms, mental retardation, insufficient knowledge of the Dutch language and previous hypnotherapy treatment.

Design outcomes

Primary

MeasureTime frame
The primary outcome will be the number of patients with > 50% reduction in intensity and frequency of abdominal pain.

Secondary

MeasureTime frame
Secondary outcomes include the change in pain scores during follow-up, IBD disease activity score, quality of life scores, depression and anxiety scores, use of additional medication, health utility, societal costs, school absence and absence of work, measured after treatment and at 3 and 6 months follow-up.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)